Johnson & Johnson Facing Asbestos Talcum Powder Lawsuits

Recently unsealed documents from a lawsuit against consumer goods and pharmaceutical giant Johnson &Johnson revealed the company knew for decades its talc products may have contained deadly asbestos fibers. The files show Johnson &Johnson was alerted of asbestos contamination risks in the early 1970s and trained employees to reassure the public its iconic baby powder products were never contaminated with the carcinogenic mineral. It is the latest chapter in the ongoing controversy over the alleged link between talcum powder and cancer. The lawsuit — filed on behalf of more than 50 women in St. Louis — is among more than 5,000 talc-related claims against J&J. Most of the lawsuits blame the company’s talc products for causing women to develop ovarian cancer, but previous lawsuits link talc to mesothelioma, a rare cancer caused almost exclusively by exposure to asbestos. In 2016, a Los Angeles Superior Court jury awarded Philip Depoian $18 million against talc supplier Whittaker, Clark &Daniels. It remains the largest verdict for mesothelioma linked to talcum powder. The St. Louis-based lawsuit against J&J alleges talc used in the company’s products “is not now, nor has it ever been, free from asbestos and asbestiform fibers.” Johnson &Johnson Ensures Products are Asbestos-Free The U.S. Food and Drug Administration (FDA) requires testing to ensure talcum powder products are asbestos free. In the lawsuit, J&J supplied ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: asbestos contamination asbestos in talcum powder asbestos lawsuits asbestos ovarian cancer Cashmere Bouquet talcum powder Colgate-Palmolive Dr. Barry Castleman Ernie Knewitz Johnson & Johnson Johnson & Johnson baby powder asbestos meso Source Type: news

Related Links:

The U.S. Food and Drug Administration moved closer on Tuesday to formulating standardized testing of talc-based products for the presence of toxic asbestos fibers. Experts from eight different federal agencies explained earlier recommendations at a day-long hearing. The session also featured input from 25 members of the public, which included industry representatives, consumer advocates and testing experts. “Standards are needed,” said Dr. Paul Howard, FDA Office of Regulatory Science, during his presentation. “They just don’t exist at this time.” Dr. Linda Katz, director of the FDA Office of ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A new 33-patient case study published in the Journal of Occupational and Environmental Medicine provides some of the strongest proof yet that exposure to asbestos-tainted talcum powder may cause malignant mesothelioma, a rare and deadly cancer that affects tissues lining internal organs. This isn’t only an important scientific discovery—it could also give new ammunition to plaintiffs in the thousands of cases brought against brands selling talcum-powder-based products alleged to cause cancer, like Johnson &Johnson’s Baby Powder. “It’s very, very hard, in general, to prove exactly what caus...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Environmental Health HealthSummit19 Research toxins Source Type: news
A mesothelioma patient at West Cancer Center in Memphis, Tennessee, is the first in the country to use NovoTTF-100L, a noninvasive electric therapy treatment, since its approval by the U.S. Food and Drug Administration in May. The FDA’s approval of Novocure’s Tumor Treating Fields device for the treatment of mesothelioma marked the first new FDA-approved treatment option for the rare asbestos-related cancer in more than 15 years. NovoTTF-100L uses a low-voltage electrical field that is distributed with three pads attached to the front and back of a person’s chest. The electrical current is designed to di...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
A research team from the Duke University Medical Center and the Massachusetts Institute of Technology has uncovered a new compound with potential to make chemotherapy more effective in treating various cancers. The small-molecule inhibitor drug — JH-RE-06 — showed an ability to better-sensitize tumors to Cisplatin, the popular chemotherapy drug most often used for mesothelioma cancer patients. When combined with Cisplatin, the drug also showed an ability to prevent those tumor cells from becoming treatment resistant, a common problem with this rare cancer caused by asbestos exposure. The research was done on l...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Sarah Cannon Research Institute in Nashville, Tennessee, and MD Anderson Cancer Center in Houston have opened a much-anticipated clinical trial involving a novel T-cell therapy for patients with mesothelioma. The two institutions are establishing dosage levels and measuring efficacy of TC-210, a type of immunotherapy that targets mesothelin, a cell surface protein highly expressed in several cancers. The study also is open to patients with certain types of bile duct, ovarian and non-small cell lung cancer. Participation is based upon individual levels of mesothelin expression. Researchers at the two centers are hoping to ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More than a dozen senior officials and experts at the Environmental Protection Agency urged the EPA to ban asbestos outright, a new report shows. Two internal memos obtained by the Asbestos Disease Awareness Organization and shared with the New York Times reveal the EPA’s own scientists and lawyers advised the agency to issue a complete ban of asbestos instead of the recent regulations that only restricted its domestic use. In the memos, dated Aug. 10, 2018, EPA staff members wrote that the agency “should seek to ban all new uses of asbestos because the extreme harm from this chemical substance outweighs any ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452). PMID: 31064781 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Children | Environmental Health | Food and Drug Administration (FDA) | History of Medicine | Italy Health | Lawsuits | Legislation | Lung Cancer | Mesothelioma | Minerals | Ovarian Cancer | Ovaries | Study | Toxicology | Websites | Women